B-type Natriuretic Peptide in the Non-Cardiac Pediatric Patient

NCT00330811 | Completed

• 1 other identifier: 1409-2005
• Study Type: observational
• Target: 87
• Locations: 1 country
• Sites: 1

Brief Summary

B-type Natriuretic Peptide (BNP) is a hormone that is made by the pumping chambers of the heart. The BNP level can be measured by a blood test and is used as a marker for heart problems in adults. Deciding if a child has a heart problem or a lung problem can be very difficult, especially in infants. Several studies have demonstrated that BNP levels are elevated when children have heart disease. The overall goal of the study is to be able to prove that obtaining BNP levels in pediatric patients can be used to identify heart problems. We already know that kids with heart problems have high BNP levels (\>200pg/ml). We need to prove that children who come to the Emergency Department for non-cardiac problems still have normal BNP levels (\<100pg/ml, slightly higher in the newborn population). This will be done by comparing BNP levels with the final diagnosis made by the ED physician.

Conditions

Heart Diseases

Keywords

Pediatrics; Non-cardiac Illness; B-type Natriuretic Peptide (BNP)

Eligibility Criteria

• Age: 1 Day - 5 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

Any child who is less than 6 years old seen in the Emergency Department evaluated for respiratory and/or infectious disease with order/s to have blood draw.

You may qualify if:

• Any child presenting to the pediatric ED at Children's Healthcare of Atlanta (CHOA)at Egleston undergoing evaluation for respiratory and/or infectious disease.
• Patient age is less than 6 years old.
• Patients having venipuncture for lab studies as a part of the ED admission.
• Informed consent being obtained from the legal guardians.

You may not qualify if:

• Patients with known congenital or acquired heart disease.
• Patients with previously diagnosed systemic disease such as malignancy, HIV, cystic fibrosis, organ transplant recipients.
• Patients that will not be having venipuncture for lab studies as a part of the ED admission.
• Trauma patients or those presenting with broken bones, dog bites, etc. (non-infectious presentation.)

Sponsors & Collaborators

• Emory University: lead

Study Sites (1)

Children's Healthcare of Atlanta

Atlanta, Georgia, 30322, United States

Location

MeSH Terms

Conditions

Heart Diseases

Condition Hierarchy (Ancestors)

Cardiovascular Diseases

Study Officials

• Kevin O Maher, MD

  Emory University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor of Pediatrics

Study Record Dates

• First Submitted: May 25, 2006
• First Posted: May 29, 2006
• Study Start: April 1, 2006
• Primary Completion: January 1, 2007
• Study Completion: May 1, 2007
• Last Updated: December 2, 2016

Record last verified: 2016-11

Locations

US (1)